Furthermore, galunisertib has been tested in preclinical models and was found to attenuate the ovarian cancer cell line response to TGF-β signaling, as well as reduce tumor burden and ascites formation in ovarian cancer patient-derived xenograft (PDX) models [108]. The gene discussed is TGFB1; the disease is ovarian cancer.